Royce & Associates’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Royce & Associates’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-879,841	Closed	-$15.8M	–	1319
2017 Q4	$15.8M	Sell	879,841 -291,890	-25%	-$3.59M	0.11%	276
2017 Q3	$13.8M	Buy	1,171,731 +103,808	+10%	+$1.16M	0.09%	300
2017 Q2	$11.2M	Buy	1,067,923 +93,900	+10%	+$957K	0.07%	362
2017 Q1	$10.7M	Buy	974,023 +192,000	+25%	+$2.23M	0.07%	366
2016 Q4	$10.6M	Buy	782,023 +225,710	+41%	+$3.15M	0.07%	370
2016 Q3	$6.85M	Buy	556,313 +188,797	+51%	+$2.22M	0.05%	485
2016 Q2	$4.03M	Buy	367,516 +350,057	+2,005%	+$3.92M	0.03%	647
2016 Q1	$191K	Buy	+17,459	New	+$221K	﹤0.01%	1044

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Royce & Associates's SCMP Position: Q1 2018 in Review

Royce & Associates sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 879,841 shares — an estimated $15.8M sold.

Royce & Associates first reported a position in SCMP in Q1 2016 and held it in 8 quarters. The position peaked at $15.8M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

Royce & Associates reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Royce & Associates sold 879,841 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $15.8M.
Royce & Associates first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2016 and held it in 8 quarters.
Royce & Associates's Sucampo Pharmaceuticals, Inc. position peaked at $15.8M in Q4 2017.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Royce & Associates's 13F filing for Q1 2018, filed 14 May 2018.